Menu
Advanced
Structure search
List search
EN
CN
ES
FR
JP
KR
Wish Lists
Cart
Sign in
Sign in
Contact us
Catalog
of Screening Compounds
Screening Libraries
Building Blocks
Advanced
Structure search
List search
Homepage
>
Company
>
Media
>
Pharma News
>
2018
Pharma News, 2018
Synergy Pharmaceuticals Announces FDA Approval of TRULANCE® (Plecanatide) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in Adults
NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals Inc.
Senate Confirms Trump Nominee Alex Azar as Health Secretary
WASHINGTON — The Senate confirmed Alex M.
LUTATHERA® marks first FDA Approval for a Peptide Receptor Radionuclide Therapy (PRRT)
SAINT-GENIS-POUILLY, France, Jan.
Do brands matter in pharma? Not as much as outcomes, patients say: study
Pharma companies should be thinking about promoting evidence-based solutions that will appeal to patients, Accenture Life Sciences Managing Director Jim Cleffi says.
Johnson & Johnson drops out of the race for Pfizer consumer unit, paving the way for GSK, Reckitt
J&J won't bid for Pfizer's OTC unit before a Feb.
New generics company emerges from unlikely source
There will soon be a new generics manufacturer to contend with — one that comes with a built-in base of 450 hospitals.
China, Unhampered by Rules, Races Ahead in Gene-Editing Trials
HANGZHOU, China—In a hospital west of Shanghai, Wu Shixiu since March has been trying to treat cancer patients using a promising new gene-editing tool.
Trovagene Announces Initiation of UNITE Phase 2 Clinical Trial of PCM-075 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
SAN DIEGO, CA, USA I January 24, 2018 I Trovagene, Inc.
Researchers develop synthetic, bacteria-killing virus
Jan.
Puma Biotechnology sinks after Europe unlikely to OK breast cancer drug
(Reuters) - Puma Biotechnology Inc said on Tuesday a European regulatory panel indicated it was unlikely to provide a positive opinion on the company’s breast cancer drug, sending its shares...
GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Announce Publication of Landmark Epidiolex® (cannabidiol) Study in The Lancet
LONDON and CARLSBAD, Calif.
ChemoCentryx Announces Positive Overall Survival Results with CCR2 Inhibitor CCX872 for Locally Advanced/Metastatic Pancreatic Cancer
MOUNTAIN VIEW, Calif.
63
64
65
66
67
68
69
70
71
0
item
s
in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Preplated libraries
Inhibitors and Approved Drugs
Screening Compounds
Building blocks
Inhibitors and approved drugs
Drug Discovery Services
Custom chemistry. Chemistry FTE. Resynthesis.
Hit Follow up Support
Medicinal chemistry FTE
In silico drug design (CADD)
Discovery Biology. Biology FTE. In vitro studies.
Animal models
Toxicology and safety
ADME, DMPK. In vivo studies
Chemistry, manufacturing and controls
Company
News & Media
Contact us
Trends in discovery compounds
